Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on EBR Systems.
RELATED STOCKHEAD STORIES
Health & Biotech
ASX Health Stocks: EBR stumbles 11pc after warning of FDA delay; Firebrick’s trial data shows ‘inaccuracies’
News
Top 10 at 11: An Indian IPO, takeover moves and mineral finds are moving the small caps today
News
Top 10 at 11: A mixed morning for lithium news and graphene is still on the boil
Health & Biotech
ScoPo’s Powerplays: Should have stayed in bed as ASX stocks fall but Neuren makes S&P ASX 200
Health & Biotech
ScoPo’s Powerplays: ASX health stocks rise as big names ‘trading at very attractive fundamentals’
Health & Biotech
ASX Health Stocks: Invex granted orphan drug designation in Europe; Resonance has a new CEO
Health & Biotech
ScoPo’s (actually Iain’s) Powerplays: ASX health stocks fall as CSL faces FX headwinds
Experts
SUNDAY ROAST: The small caps that lit a fire under Stockhead’s experts this week
Experts
Dr Boreham’s Crucible: EBR’s successful safety test looks like a proper heartstarter
Health & Biotech
Check Up: Here’s how diabetes drugs can help you get off the beers and lose weight
Health & Biotech
Pop the champagne as EBR becomes latest ASX biotech to achieve key catalyst
Health & Biotech
ScoPo’s Powerplays: ASX health stocks rise, Immutep surges 46pc on trial results
Health & Biotech
ScoPo’s Powerplays: ASX health stocks rise as Proteomics inks Sonic deal
Health & Biotech
ScoPo’s (he’s back) Powerplays: ASX health stocks fall, Volpara ‘elephants’ strategy pays off
Health & Biotech
ScoPo’s (actually still Iain’s) Powerplays: ASX health sector falls, but several stocks on upward run
Health & Biotech
ScoPo’s Powerplays: ASX health stocks rise, ImpediMed surges 99% on NCCN guidelines update
News
